Anticancer Peptides: How They Kill Tumor Cells

Anticancer Peptides

1,000+ clinical trials

Over 1,000 peptide-based cancer trials are registered in the NIH database, with more than 20 anticancer peptides approved by the FDA and EMA.

Xie et al., Open Biology, 2020

Xie et al., Open Biology, 2020

View as image

Cancer cells are not just fast-dividing normal cells. Their membranes carry a molecular signature that sets them apart: an outer surface studded with negatively charged phospholipids, higher concentrations of certain glycoproteins, and altered cholesterol content. Anticancer peptides exploit these differences. These short sequences of 10 to 60 amino acids can distinguish malignant cells from healthy tissue and destroy them through mechanisms that conventional chemotherapy cannot easily replicate. Over 1,000 peptide-based cancer clinical trials are now registered, and more than 20 anticancer peptides have received FDA or EMA approval.^[1] This article maps the full landscape of how these peptides work, from membrane-lytic killing to intracellular target engagement to immune system activation.

Why cancer cell membranes are different

The selectivity of anticancer peptides begins with a fundamental biochemical asymmetry. Healthy mammalian cells maintain an asymmetric lipid distribution across their plasma membrane: negatively charged phosphatidylserine (PS) is confined almost exclusively to the inner leaflet. Cancer cells lose this asymmetry. PS migrates to the outer membrane surface, creating a net negative charge that cationic peptides recognize and bind.^[9]

This is not a subtle difference. Riedl et al. (2015) demonstrated that human lactoferricin-derived peptides specifically targeted PS-enriched cancer cell membranes of melanoma, glioblastoma, and rhabdomyosarcoma lines while leaving non-cancerous cells intact. When they engineered peptides with loop structures that enhanced PS binding, cancer cell killing improved with no increase in toxicity to healthy fibroblasts.^[9]

Beyond PS exposure, cancer cells also display increased numbers of O-glycosylated mucins, higher levels of sialic acid-bearing glycoproteins, and elevated heparan sulfate proteoglycans on their surfaces. These molecules contribute additional negative charge. At the same time, cancer cell membranes typically contain less cholesterol than healthy cells, making them more fluid and susceptible to peptide insertion and disruption.^[1]

The net result: a cancer cell membrane is both more negatively charged and more physically vulnerable than a normal cell membrane. Cationic anticancer peptides, typically carrying a net charge of +2 to +9, preferentially accumulate on these surfaces through electrostatic attraction before executing their lethal mechanisms.

How amphipathic peptides destroy cancer cell membranes

The largest and most studied class of anticancer peptides kills cancer cells by physically tearing apart their membranes. These amphipathic peptides carry both positively charged and hydrophobic regions arranged along an alpha-helical backbone. After electrostatic docking to the cancer cell surface, the hydrophobic face inserts into the lipid bilayer.

Three primary models describe what happens next. In the barrel-stave model, peptides insert perpendicularly through the membrane to form transmembrane pores lined by peptide molecules. In the carpet model, peptides accumulate parallel to the membrane surface until reaching a threshold concentration that causes catastrophic membrane dissolution. In the toroidal pore model, peptides induce the lipid molecules themselves to curve inward, forming pores lined by both peptide and lipid headgroups.^[2]

Bui et al. (2025) explored these mechanisms using Mastoparan AF derivatives, cationic amphipathic peptides from wasp venom. Through systematic amino acid modifications, they increased the selectivity of these peptides for cancer cell membranes over erythrocytes. Circular dichroism spectroscopy confirmed that modifications preserving the alpha-helical conformation maintained anticancer potency, while those disrupting helicity reduced membrane-lytic activity. They also combined modified Mastoparan derivatives with the oncolytic peptide LTX-315 and observed synergistic killing of cancer cells.^[5]

A particularly inventive approach to the selectivity problem came from Ning et al. (2026), who engineered Charge-Alternating Spherical Membrane-Lytic Peptide (CAS-MLP) bottlebrushes. These nanostructures masked the membrane-lytic peptides behind a pH-sensitive shield. At the slightly acidic pH found in tumor microenvironments (pH 6.5-6.8), the shield unmasked, exposing the active peptide. The redox-responsive backbone then degraded in the presence of intracellular glutathione, releasing individual membrane-lytic peptide units. This dual-gating system achieved selective tumor lysis while dramatically reducing the hemolysis that limits conventional membrane-active peptides.^[14]

Melittin, a 26-amino acid peptide from bee venom, exemplifies both the promise and the challenge. Yue et al. (2026) used molecular dynamics simulations to study how melittin interacts with cancer cell membranes enriched in sialic acid. They found that sialic acid on cancer cell surfaces provided initial binding sites for the cationic peptide, increasing local peptide concentration and accelerating pore formation. When combined with cold atmospheric plasma treatment, the synergistic membrane damage exceeded what either approach achieved alone.^[15]

LTX-315: an oncolytic peptide that triggers anti-tumor immunity

Not all membrane-disrupting peptides simply lyse cancer cells and stop there. LTX-315, a synthetic nonapeptide derived from structure-activity studies on bovine lactoferricin, represents a class of oncolytic peptides that kill tumor cells and simultaneously activate the immune system against surviving cancer.

Eike et al. (2015) showed that LTX-315 killed human melanoma cells not by classical apoptosis but by inducing mitochondrial membrane disruption. The peptide caused massive mitochondrial swelling, cristae destruction, and release of cytochrome c. This mitochondria-targeted cell death triggered the release of damage-associated molecular patterns (DAMPs), including HMGB1 and ATP, molecular alarm signals that recruit and activate dendritic cells.^[6]

The immunological consequences proved striking. Camilio et al. (2014) treated B16 melanoma-bearing mice with intratumoral LTX-315 injections and achieved complete tumor regression in treated animals. More remarkably, when the researchers re-challenged cured mice with the same tumor cells, the animals rejected the tumors without additional treatment. Analysis revealed that LTX-315 treatment had generated a systemic, long-lasting anti-tumor immune response dominated by CD8+ cytotoxic T cells infiltrating the tumor site.^[7]

This dual action, direct tumor killing plus immune activation, positions oncolytic peptides as potential partners for checkpoint immunotherapy. The peptide does the initial tumor destruction and releases tumor antigens in an immunogenic context; the immune system does the long-term surveillance.

Pro-apoptotic peptides: targeting the mitochondrial death pathway

While membrane-lytic peptides attack the plasma membrane from outside, pro-apoptotic peptides penetrate the cell and trigger its internal self-destruction program. The mitochondrial pathway of apoptosis is a particularly attractive target because cancer cells often evade death by overexpressing anti-apoptotic proteins like BCL-2, BCL-XL, and MCL-1.

The KLA peptide, with the sequence (KLAKLAK)₂, is among the most studied pro-apoptotic anticancer peptides. This 14-residue amphipathic sequence has minimal effect on the plasma membrane at therapeutic concentrations but rapidly disrupts mitochondrial membranes once inside the cell, collapsing the mitochondrial membrane potential and triggering cytochrome c release. Cho et al. (2026) reviewed decades of KLA research and found that the peptide's main limitation, poor cellular uptake, has been addressed through conjugation with cell-penetrating peptides, tumor-homing sequences, and nanoparticle delivery systems. These delivery strategies improved tumor targeting while maintaining the peptide's mitochondrial specificity.^[8]

The BH3 domain represents another pro-apoptotic strategy. BCL-2 family proteins regulate mitochondrial apoptosis through protein-protein interactions mediated by BH3 domains, short alpha-helical segments that fit into hydrophobic grooves on anti-apoptotic proteins. Walensky et al. (2004) introduced hydrocarbon stapling to stabilize BH3 peptides, creating SAHBs (Stabilized Alpha-Helix of BCL-2 domains). These stapled peptides bound BCL-2 family proteins with enhanced affinity, resisted protease degradation, penetrated cell membranes, and activated apoptosis in leukemia cells both in vitro and in xenograft models.^[3]

This work established a principle: locking peptides into their bioactive alpha-helical conformation through chemical stapling creates drug-like molecules from sequences that would otherwise be too unstable and impermeable for therapeutic use.

Stapled peptides: engineering stability into anticancer peptides

Stapled peptides address three fundamental problems that limit conventional peptides as drugs: rapid protease degradation, poor membrane permeability, and loss of the alpha-helical structure required for target binding. The hydrocarbon staple, a covalent bridge between amino acid side chains spanning one or two helical turns, constrains the peptide backbone and simultaneously creates a hydrophobic surface that facilitates cell entry.

The clinical validation of this technology came with sulanemadlin (ALRN-6924). Guerlavais et al. (2023) described its development as the first cell-permeating, stabilized alpha-helical peptide to enter clinical trials. Sulanemadlin mimics the N-terminal transactivation domain of p53 and binds with high affinity to both MDM2 and MDMX, the two endogenous inhibitors of the p53 tumor suppressor. In tumors that retain wild-type p53 but overexpress MDM2 or MDMX, the peptide releases p53 from inhibition, reactivating the apoptotic program.^[4]

Choudhury et al. (2025) investigated how different hydrocarbon cross-linker lengths and positions affect the structure and binding of stapled p53 peptides to MDM2. Using molecular dynamics simulations, they found that the staple position relative to the binding interface critically determined both helical stability and binding affinity. Staples placed too close to the binding residues could sterically interfere with MDM2 engagement, while those placed too far away failed to stabilize the critical binding helix. The optimal positioning balanced structural rigidity with conformational freedom at the binding interface.^[12]

Beyond p53-MDM2, stapled peptides are being developed against other intracellular cancer targets, including the p53-MDM2/MDMX axis, BCL-2 family interactions, and RAS-RAF signaling. The technology platform is flexible: the same stapling chemistry can be applied to any alpha-helical peptide interface, making it broadly applicable across intracellular protein-protein interactions in oncology.

Peptides targeting p53 pathway reactivation

The p53 tumor suppressor is mutated or functionally inactivated in the majority of human cancers. In the approximately 50% of cancers that retain wild-type p53, the protein is often suppressed by overexpressed MDM2 or MDMX, which bind p53 and mark it for proteasomal degradation. Peptides that block this interaction can reactivate p53 signaling and restore the cancer cell's ability to undergo apoptosis.

Philippe et al. (2021) developed "Angler Peptides," macrocyclic conjugates designed to inhibit both p53:MDM2 and p53:MDMX interactions. By conjugating high-affinity p53-mimicking peptides with cell-penetrating peptide sequences, they achieved cytosolic delivery and demonstrated apoptosis activation in cancer cells. The macrocyclic structure provided both protease resistance and conformational constraint, improving binding affinity over linear peptide counterparts.^[11]

Kang et al. (2025) took a different approach, targeting the FOXO4-p53 interaction instead of MDM2-p53. In senescent cancer cells, FOXO4 binds and sequesters p53 in the nucleus, preventing it from triggering apoptosis. Their optimized peptide, CPP-CAND, disrupted this interaction and induced apoptosis selectively in senescent cancer cells while sparing non-senescent cells. This selectivity for cellular senescence represents a fundamentally different targeting strategy: rather than distinguishing cancer from normal tissue by membrane composition, the peptide distinguishes by cellular state.^[13]

Natural peptides with anticancer activity

Many anticancer peptide candidates derive from natural host defense peptides found across species. These molecules evolved to kill pathogens through membrane disruption, and their selectivity for negatively charged membranes translates into preferential activity against cancer cells.

Lactoferricin, derived from bovine lactoferrin, has been extensively studied for anticancer activity. Grissenberger et al. (2020) designed optimized human lactoferricin derivatives and tested them against malignant melanoma in both conventional 2D cultures and 3D tumor spheroid models. The peptides induced apoptosis in melanoma cells and specifically targeted lipid-enriched membrane domains. Testing in 3D spheroids, which better mimic the tumor microenvironment, confirmed activity under more physiologically relevant conditions.^[10]

Cecropin-magainin hybrid peptides combine structural elements from insect (cecropin A) and amphibian (magainin 2) antimicrobial peptides. These hybrids consistently show antitumor activity across multiple cancer cell lines while maintaining selectivity over healthy cells. The structure-activity relationship is well characterized: net positive charge drives membrane selectivity, helicity determines membrane insertion depth, and hydrophobicity modulates the balance between anticancer potency and hemolytic toxicity.^[2]

Magainin 2, originally isolated from the skin of the African clawed frog Xenopus laevis, was among the earliest antimicrobial peptides shown to kill cancer cells. Its IC50 against lung cancer A549 cells is approximately 110 micrograms per milliliter, higher than the concentrations achievable in vivo without modification. This illustrates a recurring theme: natural anticancer peptides often possess the right selectivity mechanism but lack the potency or stability for direct clinical use. The value of studying them lies in identifying the structural principles, charge distribution, amphipathic helix geometry, and membrane interaction dynamics, that can be optimized in synthetic derivatives.^[1]

Alpha-defensins, the small cationic peptides released by neutrophils during innate immune responses, also demonstrate anticancer properties. Their beta-sheet structures and disulfide-stabilized folds give them membrane-penetrating abilities distinct from the alpha-helical ACPs, expanding the structural repertoire of peptide-based cancer therapeutics.

Classification of anticancer peptides by mechanism

Xie et al. (2020) proposed a systematic classification of ACPs into four functional categories:^[1]

Membrane disruptors physically breach the cancer cell membrane through pore formation or carpet-like dissolution. This is the fastest-acting mechanism and the most resistant to drug resistance development because it targets the lipid membrane itself rather than a specific protein.

Apoptosis inducers trigger programmed cell death through mitochondrial membrane disruption, caspase cascade activation, or release of pro-apoptotic factors. These peptides must penetrate the plasma membrane to reach intracellular targets.

Angiogenesis inhibitors block the formation of new blood vessels that tumors require for sustained growth. Some peptides target VEGF receptors or downstream signaling; others interfere with endothelial cell migration.

Immune modulators activate anti-tumor immune responses by stimulating dendritic cell maturation, enhancing T cell cytotoxicity, or releasing tumor antigens in immunogenic contexts. LTX-315 falls into both the membrane disruptor and immune modulator categories.

Gaspar et al. (2013) noted that many anticancer peptides originally identified as antimicrobial peptides exhibit multiple mechanisms simultaneously. A single peptide might disrupt the plasma membrane at high concentrations, trigger mitochondrial apoptosis at lower concentrations, and activate immune cells through DAMP release. This multi-modal activity is both an advantage, it reduces resistance risk, and a challenge for rational drug design.^[2]

Current limitations and open questions

Anticancer peptides face several obstacles between the laboratory and the clinic. Serum stability remains the most universal challenge: unmodified peptides are degraded by proteases within minutes of entering the bloodstream. Strategies to address this include D-amino acid substitution, cyclization, hydrocarbon stapling, and PEGylation, each with trade-offs in cost, activity, and immunogenicity.

Selectivity is imperfect. While the electrostatic basis of cancer cell targeting is well established, ACPs are not binary switches. At high enough concentrations, most cationic peptides will damage healthy cell membranes. The therapeutic window, the concentration range that kills cancer cells without significant toxicity to normal tissue, varies widely across peptides and cancer types. Hemolysis of red blood cells is the most common dose-limiting toxicity.

Tumor penetration presents another barrier, particularly for solid tumors. Peptides that work well on isolated cancer cells or small tumor spheroids may fail against large, poorly vascularized tumors with dense stromal tissue. Delivery technologies including nanoparticle encapsulation, peptide-drug conjugates, and tumor-homing sequences are being developed to address tissue-level distribution.

Manufacturing cost exceeds that of small-molecule drugs, though advances in recombinant production and solid-phase synthesis have reduced prices considerably. The relatively short sequences of most ACPs (10-60 amino acids) make them more accessible than larger biologic drugs like antibodies.

The evidence base, while growing rapidly, still relies heavily on in vitro studies and mouse models. Translation to human clinical outcomes has been slower than the preclinical data would suggest. The gap between IC50 values measured in cell culture and effective concentrations achievable in human tumors remains one of the largest uncertainties in the field. Representative IC50 values from cell culture span a wide range: aurein 1.2 showed activity at 2 micromolar against glioblastoma T98G cells, while magainin II required 110 micrograms per milliliter against lung cancer A549 cells. Modified peptides have closed this gap; for example, the S25K modification reduced IC50 from 13.2 micromolar to 1.4 micromolar in cervical cancer cells.^[1] Whether these optimized in vitro potencies translate to effective tumor concentrations in patients remains an open question for each candidate.

Combination strategies may offer a path forward. Pairing anticancer peptides with conventional chemotherapeutics, checkpoint inhibitors, or other peptides (as Bui et al. demonstrated with Mastoparan AF and LTX-315 combinations) can achieve synergistic killing at lower individual peptide concentrations, potentially widening the therapeutic window.^[5]

The Bottom Line

Anticancer peptides exploit fundamental differences between cancer and normal cell membranes to achieve selective tumor killing. The evidence spans membrane-lytic peptides that physically destroy cancer cells, pro-apoptotic sequences that trigger mitochondrial death pathways, stapled peptides that reach intracellular targets like p53-MDM2, and oncolytic peptides that combine direct killing with immune activation. Over 20 ACPs have reached clinical approval, and sulanemadlin demonstrated that stapled peptides can enter clinical development as a viable drug class. The field's main unresolved challenges are serum stability, achieving sufficient therapeutic windows, and translating preclinical potency into clinical efficacy in solid tumors.

Frequently Asked Questions

What are anticancer peptides and how do they work?

Anticancer peptides (ACPs) are short amino acid sequences, typically 10 to 60 residues long, that selectively target and kill cancer cells. They work through multiple mechanisms: disrupting cancer cell membranes via electrostatic attraction to negatively charged phosphatidylserine, triggering mitochondrial apoptosis, inhibiting tumor blood vessel formation, and activating anti-tumor immune responses. Xie et al. (2020) classified ACPs into four functional categories based on these mechanisms.

Why do anticancer peptides kill cancer cells but not normal cells?

Cancer cells expose phosphatidylserine on their outer membrane surface, carry more negatively charged glycoproteins and sialic acid, and have lower cholesterol content than healthy cells. Cationic anticancer peptides (net charge +2 to +9) are electrostatically attracted to these negatively charged cancer surfaces. Riedl et al. (2015) confirmed this selectivity by showing that lactoferricin-derived peptides targeted PS-rich cancer membranes of melanoma, glioblastoma, and rhabdomyosarcoma cells while leaving normal fibroblasts intact.

What is a stapled peptide in cancer treatment?

A stapled peptide is a synthetic peptide reinforced with a hydrocarbon bridge that locks it into an alpha-helical shape. This staple improves protease resistance, cell membrane permeability, and target binding affinity. Walensky et al. (2004) introduced the technology by creating stabilized BH3 peptides (SAHBs) that activated apoptosis in leukemia cells. The first stapled peptide to reach clinical trials was sulanemadlin (ALRN-6924), which targets the p53-MDM2/MDMX interaction in cancer.

What is LTX-315 and what does it do to tumors?

LTX-315 is a synthetic nine-amino-acid oncolytic peptide derived from bovine lactoferricin. It kills cancer cells by disrupting their mitochondrial membranes, causing the release of damage-associated molecular patterns (DAMPs) that activate anti-tumor immunity. Camilio et al. (2014) showed that intratumoral LTX-315 injection achieved complete regression of B16 melanomas in mice, and cured animals rejected tumor re-challenge, demonstrating long-lasting immune memory.

How many anticancer peptides are FDA approved?

As of 2020, more than 20 anticancer peptides had been approved by the FDA and EMA, according to Xie et al. (Open Biology, 2020). Approved examples include carfilzomib (Kyprolis), lutetium Lu-177 dotatate (Lutathera), and gallium Ga-68 dotatoc. Over 1,000 peptide-based cancer clinical trials are registered in the NIH database, indicating substantial ongoing development beyond currently approved agents.

Can cancer cells become resistant to anticancer peptides?

Cancer cells are less likely to develop resistance to membrane-targeting anticancer peptides compared to conventional chemotherapy. Changing the fundamental lipid composition of the cell membrane is far more difficult for a cancer cell than mutating a single drug target protein. Gaspar et al. (2013) noted that the multi-modal mechanisms of many ACPs, simultaneously disrupting membranes and triggering apoptosis, further reduce resistance risk. However, resistance through increased cholesterol content or reduced surface charge has been observed in laboratory studies.